Senolytics will fail as monotherapy—the future is senolytic cycling

Dasatinib + Quercetin works in mice. Fisetin works in mice. But here's what nobody's discussing: senescent cells are not a static population. Kill them today, new ones form tomorrow. And the immune system that should clear them is itself senescing.

Current senolytic trials use intermittent monthly dosing assuming slow accumulation. But senescent cell formation rates vary dramatically by tissue and are accelerated by the inflammation that clearance triggers.

When you kill senescent cells, neighbors must proliferate to replace them. Rapid proliferation drives replicative senescence via telomere shortening. Each senolytic pulse creates a transient wave of new senescent cells 4-8 weeks later—exactly when the next dose hits.

What we need is senolytic cycling:

• Phase 1 (Week 1): Aggressive senolytic pulse (D+Q)
• Phase 2 (Weeks 2-4): Senomorphic support (rapamycin low-dose) to suppress SASP in newly-forming senescent cells
• Phase 3 (Weeks 5-6): Immune support (thymic peptides, IL-7) to boost natural clearance
• Phase 4 (Weeks 7-8): Repeat

Baker et al. (Nature 2016) showed genetic clearance of p16+ cells (continuous, not pulsed) extended lifespan 25%. Pharmacological intermittent approaches show 10-15% healthspan extension. The gap may be the rebound effect.

Testable prediction: A cycling protocol combining senolytics, senomorphics, and immunostimulants will show >2x healthspan benefit of senolytics alone in aged mice.

This needs a decentralized trial network. Who's running it?